Black Diamond Therapeutics, Inc. financial data

Symbol
BDTX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
One Main Street, 14 Th Floor, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Aset Therapeutics, Inc. (to 1/4/2018)
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 752 % -0.96%
Debt-to-equity 33.7 % -11.2%
Return On Equity -69.1 % +10.4%
Return On Assets -51.7 % +7.57%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 56.5M shares +9.56%
Common Stock, Shares, Outstanding 56.4M shares +54.4%
Entity Public Float 115M USD +106%
Common Stock, Value, Issued 7K USD +40%
Weighted Average Number of Shares Outstanding, Basic 55.2M shares +51%
Weighted Average Number of Shares Outstanding, Diluted 55.2M shares +51%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 57.5M USD -1.4%
General and Administrative Expense 29.7M USD +9.16%
Operating Income (Loss) -87.2M USD -1.96%
Nonoperating Income (Expense) 6.69M USD +32.3%
Net Income (Loss) Attributable to Parent -80.5M USD +2.67%
Earnings Per Share, Basic -1.5 USD/shares +34.2%
Earnings Per Share, Diluted -1.5 USD/shares +34.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 32.8M USD -21.7%
Assets, Current 127M USD +36.3%
Property, Plant and Equipment, Net 1.56M USD -30.8%
Operating Lease, Right-of-Use Asset 20.5M USD -12.4%
Other Assets, Noncurrent 337K USD
Assets 150M USD +25.1%
Accounts Payable, Current 763K USD -72.1%
Employee-related Liabilities, Current 3.49M USD +16.4%
Accrued Liabilities, Current 17.7M USD +58.4%
Liabilities, Current 18.4M USD +32.7%
Operating Lease, Liability, Noncurrent 20.5M USD -13.7%
Liabilities 39M USD +3.41%
Accumulated Other Comprehensive Income (Loss), Net of Tax -115K USD +82.6%
Retained Earnings (Accumulated Deficit) -456M USD -21.5%
Stockholders' Equity Attributable to Parent 111M USD +35.1%
Liabilities and Equity 150M USD +25.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21.2M USD -5.83%
Net Cash Provided by (Used in) Financing Activities 4.13M USD +7998%
Net Cash Provided by (Used in) Investing Activities -13.7M USD -155%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 56.4M shares +54.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -30.8M USD -738%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 33.6M USD -22%
Deferred Tax Assets, Valuation Allowance 111M USD +26.6%
Deferred Tax Assets, Gross 117M USD +24%
Operating Lease, Liability 23.8M USD -11.1%
Depreciation 86K USD -29.5%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -80M USD +1.39%
Lessee, Operating Lease, Liability, to be Paid 28.2M USD -13.2%
Property, Plant and Equipment, Gross 2.53M USD -21.3%
Operating Lease, Liability, Current 3.26M USD +9.45%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.6M USD +2.73%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.48M USD +2.71%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.47M USD -22.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.72M USD +2.72%
Deferred Tax Assets, Operating Loss Carryforwards 69.2M USD +14.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.93M USD -16.9%
Operating Lease, Payments 1.08M USD +2.76%
Additional Paid in Capital 567M USD +23.8%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 5.93M USD -9.88%
Share-based Payment Arrangement, Expense 11.3M USD +3.67%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%